NICE ready to work with company to address uncertainty in evidence for elacestrant for advanced breast cancer

1 October 2024 - Today NICE is consulting on draft guidance that does not recommend elacestrant for treating a type of ...

Read more →

Cabotegravir for the prevention of HIV-1 infection in adults and adolescents

26 September 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Trifluridine with tipiracil hydrochloride in combination with bevacizumab for the treatment of patients with metastatic colorectal cancer after two systemic treatments (final guidance)

25 September 2024 - NICE has published final evidence-based recommendations on the use of trifluridine with tipiracil hydrochloride (Lonsurf) for ...

Read more →

Fruquintinib approved to treat adult patients with metastatic colorectal cancer

20 September 2024 - The MHRA has today approved the new medicine fruquintinib (Fruzaqla) to treat adult patients with metastatic colorectal ...

Read more →

Fosdenopterin hydrobromide for the treatment of patients molybdenum cofactor deficiency type A

19 September 2024 - The Department of Health and Social Care has NICE to produce guidance on the use of ...

Read more →

Daiichi Sankyo’s Vanflyta recommended by NICE for acute myeloid leukaemia

19 September 2024 - Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by NICE for certain cases of acute myeloid leukaemia. ...

Read more →

Rozanolixizumab for the treatment of patients with generalised antibody positive myasthenia gravis

13 September 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Rucaparib camsylate for the maintenance treatment of patients with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (final guidance)

17 September 2024 - NICE has published final evidence-based recommendations on the use of rucaparib camsylate (Rubraca) for the maintenance ...

Read more →

Sanofi/Regeneron’s Dupixent approved by MHRA to treat uncontrolled COPD

12 December 2024 - Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the MHRA as an add-on maintenance treatment ...

Read more →

Empagliflozin for the treatment of adolescents with type 2 diabetes mellitus

12 September 2024 - NICE is unable to make a recommendation on the use of empagliflozin (Jardiance) in the NHS for ...

Read more →

Futibatinib for previously treated patients with advanced cholangiocarcinoma with FGFR2 fusion or rearrangement

11 September 2024 - NICE has published final evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 ...

Read more →

Faricimab for the treatment of patients with visual impairment caused by macular oedema after retinal vein occlusion

11 September 2024 - NICE has published final evidence-based recommendations on the use of faricimab (Vabysmo) for the treatment of ...

Read more →

Exagamglogene autotemcel for the treatment of patients 12 years of age and older with transfusion-dependent beta-thalassaemia

11 September 2024 - NICE has published final evidence-based recommendations on the use of exagamglogene autotemcel (Casgevy) for the treatment ...

Read more →

Evinacumab for the treatment of patients 12 years of age and older with homozygous familial hypercholesterolaemia

11 September 2024 - NICE has published final evidence-based recommendations on the use of evinacumab (Evkeeza) for the treatment of ...

Read more →

Pembrolizumab for adjuvant treatment of patients with resected non-small-cell lung cancer

29 August 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →